Latest News

Arix Bioscience acquires 11% stake in Phamaxis Ltd.

Pharmaxis has two approved respiratory products: Bronchitol for cystic fibrosis and Aridol for the diagnosis and assessment of asthma.


by tg

An investor consortium led by British Arix Bioscience plc has put £13.4m into the Australian Pharmaxis Ltd, which develops fibrosis inhibitors based on its amine oxidase discovery platform.

London-based Arix Bioscience announced it has acquired an 11 % interest in Pharmaxis in a two tranche placement contributing £8m, while £5.4 came from existing investors such as BVF Partners L.P. The Pharmaxis Board approved the nomination of Arix’s Edward Rayner to join the Board in September 2018. 

Arix said it will use the proceeds to advance its proprietary Phase I lead programme, an orally administered anti-fibrotic Lysyl Oxidase-Like type 2 (LOXL2) inhibitor designed to block pathogenic fibrosis, which might create treatment options for diseases such as Non-alcoholic Steatohepatitis (NASH), Idiopathic Pulmonary Fibrosis (IPF), or heart and kidney fibrosis.  The company expects to finalise Phase I testing by Q3/2018. Furthermore, the company has two preclinical development programmes. In 2015, Pharmaxis' platform was validated through a licence deal with Boehringer Ingelheim – the candidate drug BI 1467335 (formerly known as  PXS-4728A) is in Phase II testing for NASH and Diabetic Retinopathy. 

EU orders 100 million additional doses from Biontech

To avoid supply shortages that could occur as a result of restricted use of adenoviral COVID-19 vaccines, the European Commission has acquired...

B.1.1.7 variant associated with higher mortality

Previous reports from British autorities that suggested a 30 to 100% higher mortality of B.1.1.7 than of the previously dominant form in Europe are...

Media hype on Denmark’s decision to halt AZD1222 vaccination

Since Denmark suspended vaccination with AstraZeneca’s bashed Covid-19 vaccine, AZD1222 is facing questions over its safety. Denmark’s...

COVID-19: Study finds neutralising antibodies to disappear rapidly

According to the “Rhineland population-based Study”, published by researchers under  Prof. Monique Breteler at the DZNE in Bonn, Germany blood...

Swiss Oculis SA raises $57m in Series C

The financing was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing...

ADCendo ApS raises €51m in Series A financing

The investment into the spin-off company from the BioInnovation Institute (BII) in Copenhagen was led by Novo Seeds and Ysios Capital, along with RA...

Roche Phase III study misses COVID-19 endpoint

In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...